



ASX RELEASE

Chief Medical Officer resignation

EMERYVILLE, California and BRISBANE, Australia, 29 April 2008: Peplin, Inc. (ASX:PLI) today announced the resignation of Arthur Bertolino, M.D. PhD, Peplin's Chief Medical Officer and Vice President, Medical Affairs. Peter Welburn, PhD, Chief Scientific Officer and Vice President, Research and Development, will immediately assume responsibility for all clinical development and medical affairs. Dr Welburn has served as Peplin's Chief Scientific Officer and Vice President, Research and Development, since April 2001 and during that time has been responsible for all aspects of the development of PEP005, Peplin's lead compound. Through this transition Peplin expects it will maintain the ongoing progress of Peplin's lead actinic keratosis (AK) program and in particular the initiation of the phase IIb and phase III AK clinical trials targeting head and non-head treatment sites respectively.

"On behalf of the Board, I want to thank Art for his contributions and service to Peplin," said Mr. Michael Aldridge, Chief Executive Officer. "He has been instrumental in delivering positive phase II results and preparing for phase III trials of our lead compound PEP005 Topical for AK."

Further information:

Michael Aldridge
Chief Executive Officer
Tel: +1-510-653 9700
michael.aldridge@peplin.com

PEPLIN, INC.

6475 Christie Avenue, Emeryville, CA 94608, USA
Tel: +1-510-653 9700 Fax: +1-510-653 9704

Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia
Tel: +61-7-3250 1200 Fax: +61-7-3250 1299

www.peplin.com